These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 30541753)

  • 21. Identification of BRCA1/2 founder mutations in Southern Chinese breast cancer patients using gene sequencing and high resolution DNA melting analysis.
    Kwong A; Ng EK; Wong CL; Law FB; Au T; Wong HN; Kurian AW; West DW; Ford JM; Ma ES
    PLoS One; 2012; 7(9):e43994. PubMed ID: 22970155
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutation spectrum and prevalence of BRCA1 and BRCA2 genes in patients with familial and early-onset breast/ovarian cancer from Tunisia.
    Riahi A; Kharrat M; Ghourabi ME; Khomsi F; Gamoudi A; Lariani I; May AE; Rahal K; Chaabouni-Bouhamed H
    Clin Genet; 2015 Feb; 87(2):155-60. PubMed ID: 24372583
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry.
    Rosenthal E; Moyes K; Arnell C; Evans B; Wenstrup RJ
    Breast Cancer Res Treat; 2015 Jan; 149(1):223-7. PubMed ID: 25476495
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRCA1 and BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects.
    Apostolou P; Fostira F; Kouroussis C; Kalfakakou D; Delimitsou A; Agelaki S; Androulakis N; Christodoulou C; Kalbakis K; Kalykaki A; Sanidas E; Papadimitriou C; Vamvakas L; Georgoulias V; Mavroudis D; Yannoukakos D; Konstantopoulou I; Saloustros E
    Int J Cancer; 2020 Sep; 147(5):1334-1342. PubMed ID: 32022259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High frequency of BRCA1 founder mutations in Polish women with nonfamilial breast cancer.
    Gaj P; Kluska A; Nowakowska D; Bałabas A; Piątkowska M; Dabrowska M; Niwińska A; Ostrowski J
    Fam Cancer; 2012 Dec; 11(4):623-8. PubMed ID: 22864640
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of breast cancer susceptibility genes BRCA1 and BRCA2 in Thai familial and isolated early-onset breast and ovarian cancer.
    Patmasiriwat P; Bhothisuwan K; Sinilnikova OM; Chopin S; Methakijvaroon S; Badzioch M; Padungsutt P; Vattanaviboon P; Vattanasapt V; Szabo C; Saunders GF; Goldgar D; Lenoir GM
    Hum Mutat; 2002 Sep; 20(3):230. PubMed ID: 12203997
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Mutational analysis of BRCA1 and BRCA2 genes in early-onset breast cancer patients in Shanghai].
    Song CG; Hu Z; Yuan WT; Di GH; Shen ZZ; Huang W; Shao ZM
    Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(43):3030-4. PubMed ID: 16324400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary.
    Van Der Looij M; Szabo C; Besznyak I; Liszka G; Csokay B; Pulay T; Toth J; Devilee P; King MC; Olah E
    Int J Cancer; 2000 Jun; 86(5):737-40. PubMed ID: 10797299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of BRCA1 and BRCA2 large genomic rearrangements in Tunisian high risk breast/ovarian cancer families: Implications for genetic testing.
    Riahi A; Chabouni-Bouhamed H; Kharrat M
    Cancer Genet; 2017 Jan; 210():22-27. PubMed ID: 28212807
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer.
    Simard J; Dumont M; Moisan AM; Gaborieau V; Malouin H; Durocher F; Chiquette J; Plante M; Avard D; Bessette P; Brousseau C; Dorval M; Godard B; Houde L; ; Joly Y; Lajoie MA; Leblanc G; Lépine J; Lespérance B; Vézina H; Parboosingh J; Pichette R; Provencher L; Rhéaume J; Sinnett D; Samson C; Simard JC; Tranchant M; Voyer P; Easton D; Tavtigian SV; Knoppers BM; Laframboise R; Bridge P; Goldgar D
    J Med Genet; 2007 Feb; 44(2):107-21. PubMed ID: 16905680
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frequency and spectrum of founder and non-founder BRCA1 and BRCA2 mutations in a large series of Russian breast cancer and ovarian cancer patients.
    Sokolenko AP; Sokolova TN; Ni VI; Preobrazhenskaya EV; Iyevleva AG; Aleksakhina SN; Romanko AA; Bessonov AA; Gorodnova TV; Anisimova EI; Savonevich EL; Bizin IV; Stepanov IA; Krivorotko PV; Berlev IV; Belyaev AM; Togo AV; Imyanitov EN
    Breast Cancer Res Treat; 2020 Nov; 184(1):229-235. PubMed ID: 32776218
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Presymptomatic breast cancer in Egypt: role of BRCA1 and BRCA2 tumor suppressor genes mutations detection.
    Ibrahim SS; Hafez EE; Hashishe MM
    J Exp Clin Cancer Res; 2010 Jun; 29(1):82. PubMed ID: 20579331
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry.
    Fernandes GC; Michelli RA; Galvão HC; Paula AE; Pereira R; Andrade CE; Felicio PS; Souza CP; Mendes DR; Volc S; Berardinelli GN; Grasel RS; Sabato CS; Viana DV; Mauad EC; Scapulatempo-Neto C; Arun B; Reis RM; Palmero EI
    Oncotarget; 2016 Dec; 7(49):80465-80481. PubMed ID: 27741520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
    Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F
    Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer.
    Ramus SJ; Harrington PA; Pye C; DiCioccio RA; Cox MJ; Garlinghouse-Jones K; Oakley-Girvan I; Jacobs IJ; Hardy RM; Whittemore AS; Ponder BA; Piver MS; Pharoah PD; Gayther SA
    Hum Mutat; 2007 Dec; 28(12):1207-15. PubMed ID: 17688236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New recurrent BRCA1/2 mutations in Polish patients with familial breast/ovarian cancer detected by next generation sequencing.
    Kluska A; Balabas A; Paziewska A; Kulecka M; Nowakowska D; Mikula M; Ostrowski J
    BMC Med Genomics; 2015 May; 8():19. PubMed ID: 25948282
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hereditary breast cancer; Genetic penetrance and current status with BRCA.
    Mahdavi M; Nassiri M; Kooshyar MM; Vakili-Azghandi M; Avan A; Sandry R; Pillai S; Lam AK; Gopalan V
    J Cell Physiol; 2019 May; 234(5):5741-5750. PubMed ID: 30552672
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia.
    Torres D; Rashid MU; Gil F; Umana A; Ramelli G; Robledo JF; Tawil M; Torregrosa L; Briceno I; Hamann U
    Breast Cancer Res Treat; 2007 Jun; 103(2):225-32. PubMed ID: 17080309
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Founder BRCA1 and BRCA2 mutations in early-onset French Canadian breast cancer cases unselected for family history.
    Tonin PN; Perret C; Lambert JA; Paradis AJ; Kantemiroff T; Benoît MH; Martin G; Foulkes WD; Ghadirian P
    Int J Cancer; 2001 May; 95(3):189-93. PubMed ID: 11307153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
    Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
    Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.